260 related articles for article (PubMed ID: 25434595)
1. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Rubio MA
Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
[No Abstract] [Full Text] [Related]
2. Nonincretin drugs in later-stage development.
Zimmerman MP; Mehr SR
Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
[No Abstract] [Full Text] [Related]
3. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
5. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
6. Two new drugs approved for obesity.
Johnson AM
S D Med; 2012 Sep; 65(9):356-7. PubMed ID: 23066610
[No Abstract] [Full Text] [Related]
7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy for obesity: What you need to know.
Bersoux S; Byun TH; Chaliki SS; Poole KG
Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
[TBL] [Abstract][Full Text] [Related]
9. Practical Use of Pharmacotherapy for Obesity.
Igel LI; Kumar RB; Saunders KH; Aronne LJ
Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
[TBL] [Abstract][Full Text] [Related]
10. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
11. Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
[No Abstract] [Full Text] [Related]
12. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
13. Lemons for obesity.
Lauer MS
Ann Intern Med; 2012 Jul; 157(2):139-40. PubMed ID: 22801677
[No Abstract] [Full Text] [Related]
14. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
[No Abstract] [Full Text] [Related]
15. The pharmacological and surgical management of adults with obesity.
Ryan DH
J Fam Pract; 2014 Jul; 63(7 Suppl):S21-6. PubMed ID: 25198216
[No Abstract] [Full Text] [Related]
16. Pharmacologic therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
19. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
